Device dependence – European Clinical Trials Information Network

Study on Renaparin for Improving Kidney Function in Patients with End-Stage Renal Disease Receiving Deceased Donor Transplants

Mon, 04 May 2026 07:49:13 +0000

This clinical trial is focused on studying the effects of a treatment called Renaparin on patients who have received a kidney transplant from a deceased donor. The study is particularly interested in patients with end-stage renal disease, which means their kidneys are no longer able to function properly. The treatment involves using a special solution, known as Renaparin, to help preserve the kidney before it is transplanted. This solution contains a substance called Corline Heparin Conjugate, which is designed to improve the function of the transplanted kidney.

The purpose of the study is to see if Renaparin can help improve the function of the transplanted kidney, especially in patients who are at high risk of experiencing problems like ischemia-reperfusion injury and delayed graft function. These terms refer to potential complications that can occur when a kidney is transplanted, such as damage from a lack of blood flow or the kidney not working right away. The study will last for a total of 12 months, with the first 3 months being the main focus, followed by an additional 9-month follow-up period.

During the study, participants will be randomly assigned to receive either the Renaparin treatment or no treatment at all. The study is designed to be “single-blind,” meaning that the participants will not know which group they are in. Researchers will monitor the kidney function of participants by measuring various indicators, such as the estimated glomerular filtration rate (eGFR) and serum creatinine levels, at different points throughout the study. The goal is to determine if Renaparin can help improve these measures of kidney function in transplant recipients.

Study on Renaparin for Improving Kidney Function in Transplant Patients with End-Stage Renal Disease from Deceased Donors

Wed, 29 Apr 2026 14:24:57 +0000

This clinical trial is focused on studying the effects of a treatment called Renaparin on patients who have received a kidney transplant from a deceased donor. The study is particularly interested in patients with end-stage renal disease, which means their kidneys are no longer able to function properly. The treatment involves using a special solution, known as Renaparin, to help preserve the kidney before it is transplanted. This solution contains an active substance called Corline Heparin Conjugate, which is designed to improve the function of the transplanted kidney.

The purpose of the study is to see if Renaparin can help improve the function of the transplanted kidney, especially in patients who are at high risk of experiencing problems like ischemia-reperfusion injury and delayed graft function. These are conditions that can occur when the blood supply to the kidney is temporarily reduced or stopped, and then restored, which can sometimes damage the kidney. The study will last for a total of 12 months, with the first 3 months being the main focus, followed by a 9-month follow-up period.

During the study, some patients will receive the Renaparin treatment, while others will not receive any treatment, allowing researchers to compare the results. The study will monitor various aspects of kidney function, such as how well the kidney filters waste from the blood, and how often patients need dialysis, which is a treatment that helps clean the blood when the kidneys are not working well. The goal is to determine if Renaparin can help improve these outcomes for patients who have received a kidney transplant.